Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell crawled time : 09:00 save search
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
Published: 2023-09-18 (Crawled : 09:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.25%
H: 0.38%
C: -0.32%
yescarta t-cell treatment response therapy study
WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
Published: 2023-01-05 (Crawled : 09:00) - biospace.com/
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -1.28%
H: 0.35%
C: -0.29%
license agreement
Long term study confirms efficacy of ISA Pharmaceuticals' T-cell activating immunotherapy in combination with checkpoint inhibitor
Published: 2022-03-01 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -3.33%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.3%
H: 0.0%
C: 0.0%
als long term cel immunotherapy therapy t-cell
QIAGEN Launches CE-marked Version of QuantiFERON® SARS-CoV-2 to Assess T-cell Response to COVID-19
Published: 2021-12-02 (Crawled : 09:00) - biospace.com/
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
|
| O: 0.78%
H: 0.88%
C: 0.5%
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
|
| O: 0.78%
H: 0.88%
C: 0.5%
covid quantiferon t-cell sars-cov-2 response